Download PDF
Thromb Haemost 1994; 72(01): 159-160
DOI: 10.1055/s-0038-1648829
Letter to the Editor
Schattauer GmbH Stuttgart

High Dose Aprotinin Reduces Prothrombin and Fibrinogen Conversion in Patients Undergoing Extracorporeal Circulation for Myocardial Revascularization

M Spannagl
University of Munich, Department of Medicine and German Heart Center Munich, Germany
,
W Dietrich
University of Munich, Department of Medicine and German Heart Center Munich, Germany
,
A Beck
University of Munich, Department of Medicine and German Heart Center Munich, Germany
,
W Schramm
University of Munich, Department of Medicine and German Heart Center Munich, Germany
› Author Affiliations
Further Information

Publication History

Received 09 December 1993

Accepted after revision 24 March 1994

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Gebhard W, Tschesche H, Fritz H. Biochemistry of aprotinin and aprotinin-like enzymes. In: Barett A, Salvesen G. eds Protease Inhibitors. Amsterdam: Elsevier; 1986. pp 375-388
  • 2 Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay Y, Sebening F, Richter J. Influence of high dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anaesthesiology 1990; 73: 1119-1126
    CrossrefPubMedGoogle Scholar
  • 3 Kluft C. Pathomechanisms of defective hemostasis during and after extra-corporeal circulation: contact phase activation. In: Blood use in cardiac surgery Friedei N, Heitzer R, Royston D. eds Steinkopff Verlag; Darmstadt: 1991. pp 10-15
  • 4 Lu H, Soria C, Commin P, Piwnica SJA, Schumann F, Regnier O, Legrand Y. Hemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-637
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lavee J, Savion N, Smelinsky A, Goor D, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1992; 53: 477-481
    CrossrefPubMedGoogle Scholar
  • 6 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin sensitively detects the activation state of blood coagulation in vivo. Blood Coag Fibrinol 1993; 4: 097-102
    CrossrefPubMedGoogle Scholar
  • 9 Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 01-10
    PubMedGoogle Scholar
  • 10 Teufelsbauer H, Proidl S, Havel M, Vukovic Th. Early activation of hemostasis during cardiopulmonary bypass: Evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992; 68: 250-252
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Edmunds LH. Blood-surface interaction during cardiopulmonary bypass. J Cardiac Surg 1993; 8: 404-410
    CrossrefPubMedGoogle Scholar
  • 12 Boisclair MD, Lane DA, Phillippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 1993; 70: 253-258
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?. Thromb Haemost 1993; 70: 259-262
    Article in Thieme ConnectPubMedGoogle Scholar